AI SYSTEM VALIDATION · GxP · PHARMA

Validate AI systems in GxP, from intended use to controlled operation.

We validate bounded AI-enabled systems for a defined GxP use: from intended use, system boundary and risk through data and supplier evidence, requirements, acceptance criteria and testing to release, monitoring and change control. Scope, data, model, supplier, interfaces and human controls form one traceable validation package.

Regulatory anchors
  • ISPE GAMP AI
  • EU GMP Annex 11
  • Annex 22 (Draft)
  • EU AI Act
  • FDA CSA
validated systems
60+
years of practice
17+
audit pass rate
100%
critical findings
0

How do you validate an AI system in GxP?

Start with the intended use and its GxP impact, not the model label. From there the risk drives everything: which controls need evidence, how tests are shaped, when release becomes defensible.

01 Validation object

The model is only one part of the validated system.

A blanket statement that an AI model is validated is not sufficient. The validation object is the configured system in its operating context and for one approved intended use.

02 Lifecycle controls

Which lifecycle controls are required?

Six controls translate the intended use into a validation package that holds under inspection. Each row shows what must be regulated and which deliverable follows.

Control step What is regulated Deliverable
1. Inventory & intended use Owner, system boundary, process, users, data, outputs, limitations and affected decision. Intended-use and GxP impact assessment
2. GxP impact & risk Reasonably foreseeable failures and effects on patient safety, product quality and data integrity. Risk assessment and validation plan
3. Supplier, design & data Architecture, provenance, configuration, data lineage, representativeness, independence and security. Supplier and system assessment
4. Requirements & acceptance Use-specific metrics, thresholds, error classes, abstention, escalation and human review. Requirements and traceability
5. Verification & validation Independent representative tests plus interfaces, records, access, audit trails, fallback and recovery. Protocols, raw results and deviations
6. Release & operation Accountability, training, approved configuration, monitoring, incidents, change control and retest triggers. Monitoring, change and retest plan

Every row is a mandatory checkpoint, depth follows risk, not model label.

03 Risk classification

How is an AI use case classified on a risk basis?

Classification starts with the real process impact. The decisive questions are what the system influences, how autonomous the output is, whether qualified personnel can detect an error before harm, and which records or decisions depend on the result.

A vendor category or the label 'AI' does not determine validation depth. A low-autonomy drafting aid and an automated quality decision require different controls even when they use the same underlying model.

Regulatory boundary (status: 13 July 2026): EU GMP Annex 22 is currently a consultation draft and not a final effective annex. It is a relevant forward-looking reference for GMP manufacturing, not a universal rule for all GxP contexts. The final FDA CSA guidance is scoped to software used in medical-device production or quality management systems.
04 FAQ

Frequently asked questions about AI validation in GxP.

How do you validate an AI system in GxP?

Starting from intended use and GxP impact, define the system boundary, risks, data, supplier, requirements, acceptance criteria and human controls. Independent representative tests, end-to-end verification, traceability, approved release, and monitoring, change and retest rules for operation follow.

Which lifecycle controls are required for AI?

At minimum: inventory and owner, intended use, GxP and risk classification, supplier and system assessment, data governance, approved acceptance criteria, independent testing, human oversight, configuration control, monitoring, incident management, change control and defined retest triggers.

How is an AI use case classified on a risk basis?

By the effect of a failure on patient safety, product quality, data integrity and the regulated process. Autonomy, detectability of error, human intervention, data criticality and the importance of the affected decision also matter. The specific use, not the model name, determines the depth.

Must every AI system be validated?

No. Intended use and GxP impact are decisive. If the system affects a GxP process, quality-relevant decisions or GxP data, it needs documented fitness evidence at a risk-appropriate depth. Purely non-GxP uses are not automatically subject to CSV.

Is Annex 22 already binding?

No. The publicly available text is a consultation draft and not yet a final effective EU GMP annex. It indicates regulatory direction for GMP-related AI projects. Its draft status must remain clear in assessment and communication.

When is AI consulting the right entry point instead of AI system validation?

If the use case, governance, provider, architecture or operating model is still open, the buyer path starts with AI consulting. AI system validation is the right route once a specific system, intended use and potential GxP impact can be bounded and evidence for release and operation is required.

Define the validation object.
Then build the evidence.

In 30 minutes we clarify intended use, GxP impact and whether a paid validation assessment is the right next step.

60+
Projects
17+
Years
100 %
Audit-Pass
0
Findings
Book a no-strings strategy call

Free initial assessment · AI validation · GxP · Pharma

or
Call directly +49 170 7878065 Mon–Fri 8 a.m. – 5 p.m. Send an email contact@daniel-herrmann.io Reply within 24 h